RESULTS

Scanning for additive associations
The results of an additive genetic model meta-analysis are summarized in Manhattan plots ( Fig. 2 and Supplementary Fig. 2 ).
Existing knowledge of genetic variants affecting risk of coronary artery disease (CAD) is largely based on genome-wide association study (GWAS) analysis of common SNPs. Leveraging phased haplotypes from the 1000 Genomes Project, we report a GWAS meta-analysis of ~185,000 CAD cases and controls, interrogating 6.7 million common (minor allele frequency (MAF) > 0.05) and 2.7 million low-frequency (0.005 < MAF < 0.05) variants. In addition to confirming most known CAD-associated loci, we identified ten new loci (eight additive and two recessive) that contain candidate causal genes newly implicating biological processes in vessel walls. We observed intralocus allelic heterogeneity but little evidence of low-frequency variants with larger effects and no evidence of synthetic association. Our analysis provides a comprehensive survey of the fine genetic architecture of CAD, showing that genetic susceptibility to this common disease is largely determined by common SNPs of small effect size.
In total, 2,213 variants (7.6% indels) showed significant associations (P < 5 × 10 −8 ) with CAD with a low false discovery rate (FDR q value < 2.1 × 10 −4 ). When these 2,213 variants were grouped into loci, 8 represented regions not previously reported as being associated with CAD at genome-wide levels of significance ( Fig. 2 and Table 1 ). Of the 48 loci previously reported at genome-wide levels of significance, 47 showed nominally significant associations (Supplementary Table 2 ). The exception was rs6903956, the lead SNP for the ADTRP-C6orf105 locus detected in Han Chinese 6 , which previously showed no association in the Metabochip meta-analysis of Europeans and South Asians 3 . Thirty-six previously reported loci showed genome-wide significance ( Supplementary Table 2 ). Monte Carlo simulations, guided by published effect sizes, suggest that our study was powered to detect 34 of the previously reported loci (95% confidence interval (CI) = 31-41 loci) at genome-wide significance. Hence, our findings are fully consistent with the previously identified CAD-associated loci.
The majority of the loci showing GWAS significance in the present analysis were well imputed (82% with imputation quality >0.9) ( Fig. 3a) and had small effect sizes (odds ratio (OR) < 1.25) ( Fig. 3b ). An exception was the lead SNP in the newly associated chromosome 7q36.1 (NOS3) locus, rs3918226, which was only moderately well imputed (quality of 0.78), but the validity of this association was supported by existing genotype data, as rs3918226 was present on the HumanCVD BeadChip for which data were available for some of the cohorts used in the present analysis, thereby allowing directly measured genotypes to be compared with imputed genotypes ( Supplementary Table 3 ) (ref. 7) . Three additional lowerfrequency and moderately well-imputed SNPs in LPA and APOE (Fig. 3a) , which were not previously reported in CAD GWAS 3, 4 , also showed strong associations (LPA: rs10455872, P = 5.7 × 10 −39 and rs3798220, P = 4.7 × 10 −9 ; APOE: rs7412, P = 8.2 × 10 −11 ). The LPA SNPs have previously been shown to be strongly associated with CAD in candidate gene studies based on experimental genotype data 7, 8 .
A r t i c l e s
The minor allele of SNP rs7412 encodes the ε2 allele of APOE, and it has been well documented that carriers of the ε2 allele have lower cholesterol levels; significant protection from CAD by this allele was confirmed in a large meta-analysis 9 and the Metabochip study (P = 0.0009) (ref. 3) . However, rs7412 is not present on most commercially available genome-wide genotyping arrays and cannot be imputed using HapMap reference panels, highlighting the value of the expanded coverage of the 1000 Genomes Project reference panels. Finally, SNP rs11591147 in PCSK9, which encodes the low-frequency (MAF = 0.01) p.Arg46Leu substitution that has been associated with low LDL (low-density lipoprotein) cholesterol levels and cardioprotection [10] [11] [12] [13] , was imperfectly imputed (imputation quality = 0.61). Nonetheless, these data provide the strongest evidence yet for a protective effect of this variant in CAD (P = 7.5 × 10 −6 ).
Scanning for non-additive associations
Few GWAS of CAD have systematically scanned for associations that include dominance effects, and few truly recessive loci have been reported 14, 15 . We used a recessive inheritance model to search for susceptibility effects conferred by homozygosity for the minor (less frequent) allele. Two new recessive susceptibility loci were identified with MAF = 0.09 and 0.36 and genotypic OR = 0.67 and 1.12, respectively ( Fig. 2 and Table 1 ); these loci showed very little evidence of association under an additive model ( Table 1) . A supplementary analysis applying a dominant model identified multiple strong associations with variants, all of which overlapped with loci identified in the analysis applying an additive model ( Supplementary Table 4 ).
Myocardial infarction subphenotype analysis
Subgroup analysis in cases with a reported history of myocardial infarction (~70% of the total number of cases) did not identify any additional associations reaching genome-wide significance. The association results for the myocardial infarction subphenotype for the 48 previously known CAD-associated loci and the 8 new additive CADassociated loci discovered in this study are shown in Supplementary  Table 5 . The odds ratios for the lead SNPs at 56 loci for the broader CAD phenotype (full cohort) and the myocardial infarction subphenotype are compared in Supplementary Figure 3 . Although, as expected, the odds ratios were very similar for most of the loci, the odds ratios for the ABO and HDAC9 loci were sufficiently distinct in the two cohorts for their 95% confidence intervals to lie away from the line of equality, suggesting that the ABO locus preferentially associates with myocardial infarction and the HDAC9 locus preferentially associates with stable coronary disease but not myocardial infarction per se.
FDR and heritability analysis
We performed a joint association analysis to search for evidence of synthetic associations 16 , where multiple low-frequency susceptibility variants at a locus might be in LD with a common variant discovered as the lead variant in a GWAS, and to compile an FDR-defined list of informative variants for annotation and heritability analysis 3 . Variants that showed suggestive additive association (P < 5 × 10 −5 ) were assigned to 214 putative susceptibility loci of 2 cM centered on each lead variant, and all variants in these loci were examined; consequently, the search space for the joint analysis included 1,399,533 variants. Using GCTA software 17 to perform an approximate joint association analysis (Online Methods), we identified 202 FDR variants (q value < 0.05) in 129 loci ( Supplementary Table 6 ) with multiple (2-14) tightly linked variants, corresponding to 57% of the putative CAD susceptibility loci. The 202 FDR variants were mostly common (median MAF = 0.22) and well imputed (median imputation quality = 0.97). Ninety-five variants (explaining 13.3 ± 0.4% of CAD heritability) mapped to 44 significant loci from GWAS, and 93 variants (explaining 12.9 ± 0.4% of CAD heritability) mapped to loci that included a previously reported significant variant from GWAS analysis. One hundred nine variants (explaining a further 9.3 ± 0.3% of CAD heritability) mapped to other loci. Fifteen low-frequency (MAF < 0.05) variants explained only 2.1 ± 0.2% of CAD heritability, indicating that our study was ~90% powered to detect OR >1.5 with low-frequency variants ( Supplementary Table 7 ).
Common variants showing typical GWAS signals might be coupled with one or more low-frequency variants with relatively large effects 16 . We found no evidence for such synthetic associations in the joint association analysis; that is, all low-frequency variants were either a lead variant or were jointly associated (q value < 0.05) with a common variant. Twenty of the 202 FDR variants (9.9%) were indels (4-14 bp in size) as compared to 8.8% of all the variants in the meta-analysis (P = 0.60). Low-frequency variants (MAF < 0.05) The distribution for 2.5 million HapMap 2 SNPs. Imputation quality was calculated as the median of the respective values in up to 48 contributing studies; the imputation quality for genotyped variants was set equal to 1.0. The 1000 Genomes Project training set includes more lowfrequency variants, many of which have imputation qualities >0.9.
Post-hoc power calculations
Of the 9.4 million variants analyzed, 8.2 million (87%) were highly powered (>90%) to detect an OR ≥1.3 (Supplementary Table 7 ). The number of variants with power of ≥90% to detect associations varied systematically with allele frequency and imputation quality (results for OR = 1.3 shown in Supplementary Fig. 4 ); 1.5 million of the 2.7 million (55%) low-frequency variants (0.005 < MAF < 0.05) in the meta-analysis were adequately powered to detect an OR ≥1.3, as most of these variants were accurately imputed (median imputation quality = 0.94, interquartile range = 0.88-0.98). Of the more common variants (MAF > 0.05), almost all (99.8%) were highly powered to detect an OR ≥1.3. However, in terms of total coverage of low-frequency variation, only 15.3% of the 9.3 million low-frequency variants (0.005 < MAF < 0.05) in the 1000 Genomes Project phase 1 v3 training set met the allele frequency and imputation quality entry criteria in the 60% of the studies required for inclusion in the meta-analysis and were predicted to be adequately powered to detect significant associations; 100% of these variants were highly powered (>90%) to detect an OR ≥3.15.
Interrogation of ten newly identified additive and recessive loci
We examined whether there were any expression quantitative trait loci (eQTLs), associations with known cardiovascular risk factors or prior evidence of the involvement of genes with atherosclerotic processes in each of the newly identified loci to define putative mechanisms by which the loci might affect risk of CAD.
At the chromosome 4q12 (REST-NOA1) locus, the lead SNP rs17087335 lies within an intron of the NOA1 gene (nitric oxideassociated 1); 23 SNPs in LD (r 2 > 0.8) showed CAD associations (P < 1 × 10 −6 ) across the NOA1 and REST (repressor element-1 silencing transcription factor) genes ( Fig. 4a) . NOA1 encodes a GTP-binding protein involved in the regulation of mitochondrial respiration and apoptosis 19 . REST encodes a transcription factor that suppresses the expression of voltage-dependent sodium and potassium channels 20 ; it has been shown to maintain vascular smooth muscle cells (VSMCs) in a quiescent, non-proliferative state and is itself downregulated in neointimal hyperplasia 21 . SNP rs17087335 showed a cis-eQTL signal for REST in lung 22 ( Supplementary Table 14 ).
At the chromosome 7q36.1 (NOS3) locus, the lead SNP rs3918226 (MAF = 0.07) lies in the first intron of NOS3 (nitric oxide synthase 3) ( Fig. 4b) . This SNP was tentatively associated with CAD (OR = 1.14, P = 1.4 × 10 −4 ) in a candidate gene meta-analysis based on 15,600 Figure 2 A circular Manhattan plot summarizing the 1000 Genomes Project CAD association results. The meta-analysis statistics were adjusted for overdispersion (before applying double genomic control, λ = 1.18); overdispersion is predicted to be a regular feature in GWAS under a polygenic inheritance model 60 . The association statistics were capped at P = 1 × 10 −20 . Genome-wide significant variants (P < 5 × 10 −8 ) are indicated by red triangles. New CAD-associated loci are indicated by red text (table 1) . Previously reported loci showing genome-wide significant association are indicated by black text, and those showing nominal significance (P < 0.05) in our meta-analysis are indicated by blue text (supplementary table 2 ). The inner track shows the imputation quality scores of the lead variants in the new loci. The middle track shows numbered chromosome ideograms with centromeres represented by pink bars. npg A r t i c l e s cases and 35,000 controls genotyped with the HumanCVD BeadChip 7 and was firmly associated with essential hypertension (OR = 1.34, P = 1.0 × 10 −14 ) (ref. 23) . NOS3 is involved in the production of nitric oxide (NO), a potent vascular smooth muscle relaxant, and is a wellstudied candidate gene for CAD. Indeed, the genes encoding the components of the NO receptor (soluble guanylyl cyclase) display both linkage and genome-wide association with CAD 3, 24 . There are several overlapping ENCODE features in intron 1 of NOS3, suggesting a functional role for rs3918226. However, there are 30 genes neighboring NOS3 within a 2-cM window centered on this variant, and the current data do not allow the candidacy of these genes to be excluded. A nonsynonymous SNP, rs1799983, in NOS3 previously associated with cardiovascular phenotypes 25 is in weak LD with rs3918226 but did not achieve significance in the additive or joint association analysis.
At the chromosome 11p15.4 (SWAP70) locus, SNP rs10840293 is intronic to SWAP70 (switch-associated protein-70) ( Fig. 4c) . SWAP-70 is a signaling molecule involved in the regulation of filamentous actin networks 26 in cell migration and adhesion. SNP rs10840293 and other SNPs in strong LD are cis eQTLs for SWAP70 in naive and challenged monocytes 27 , with SNP rs93138 showing strong association with CAD (P = 5.5 × 10 −8 ) and being a cis eQTL for SWAP70 in naive and challenged monocytes 28 , fat 29 , skin 29 and lung 22 ( Supplementary  Table 14 ); three of the linked SNPs (rs93138, rs173396 and rs472109) are intronic and lie within ENCODE regulatory functional elements. Although this CAD-associated locus includes 33 genes, the eQTL and ENCODE data implicate SWAP70 as a plausible causal gene and suggest putative causal SNPs.
At the chromosome 15q22.33 (SMAD3) locus, the lead SNP rs56062135 is intronic to SMAD3 and the CAD association is tightly localized between two recombination hot spots ( Fig. 4d) . Mice lacking Smad3, a major downstream mediator of transforming growth factor (TGF)-β signaling, show enhanced neointimal hyperplasia with decreased matrix deposition in response to vascular injury 30 . SMAD3 was tentatively associated with CAD in an earlier GWAS 31 , although the lead SNP (rs17228212) in that association is in linkage Association results are presented for two inheritance models; results from the discovery association model are shown in bold. P values were adjusted for overdispersion following meta-analysis. Heterogeneity P values are for the respective discovery association model. Chr., chromosome; A1, effect allele; A2, non-effect allele; freq., frequency; Table 6 ). At the chromosome 15q26.1 (MFGE8-ABHD2) locus, the lead intergenic SNP rs8042271 maps 117 kb upstream of MFGE8 (milk fat globule-EGF factor 8) and 57 kb upstream of ABHD2 (abhydrolase domain-containing protein 2) ( Fig. 4e) . MFGE8 (lactadherin) has a crucial role in vascular endothelial growth factor (VEGF)-dependent neovascularization 32 , and it is secreted from activated macrophages and binds to apoptotic cells, facilitating phagocytic engulfment 33 . ABHD2 (ref. 34 ) has been shown to be expressed in human atherosclerotic lesions, with higher levels in patients with unstable angina. There were no overlapping risk factor quantitative trait locus (QTL), eQTL or ENCODE features in this locus to guide the nomination of a putative causal gene.
At the chromosome 17q23.2 (BCAS3) locus, the lead intronic SNP rs7212798 lies in BCAS3 (breast carcinoma amplified sequence 3) ( Fig. 4f) . Multiple variants in LD with rs7212798 map to BCAS3 introns and showed strong association with CAD. BCAS3 encodes Plots are shown for the 12q24.23 (KSR2) locus (i) and the 19q13.11 (ZNF507-LOC400684) locus (j). The association statistics were adjusted for overdispersion following meta-analysis (genomic control parameter = 1.18 for the additive model and 1.05 for the recessive model). LD (r 2 ) calculations were based on the combined 1000 Genomes Project phase 1 v3 training data set. Genomic coordinates refer to the hg19 sequence assembly. npg A r t i c l e s the Rudhira protein, which has been shown to activate Cdc42 to affect actin organization and control cell polarity and motility in endothelial cells, thus contributing to angiogenesis 35 .
At the chromosome 18q21.32 (PMAIP1-MC4R) locus, the lead intergenic SNP rs663129 lies 266 kb downstream of PMAIP1 (phorbol-12-myristate-13-acetate-induced protein 1) and 200 kb downstream of MC4R (melanocortin 4 receptor) ( Fig. 4g) . PMAIP1 is a hypoxiainducible factor (HIF)-1α-induced proapoptotic gene that mediates hypoxic cell death by the generation of reactive oxygen species 36 . MC4R is a well-studied obesity-related locus, and the variant (and corresponding proxy variants) that were associated with higher CAD risk are also associated with body mass index (BMI) (P = 6 × 10 −42 ) and obesity-associated risk factors, including higher triglyceride and lower high-density lipoprotein (HDL) concentrations and type 2 diabetes [37] [38] [39] [40] [41] . However, we found no eQTL data or ENCODE features for the lead or proxy SNPs to further implicate MC4R as the causal gene underlying CAD susceptibility.
At the chromosome 22q11.23 (POM121L9P-ADORA2A) locus, the lead SNP rs180803 lies in POM121L9P (encoding the noncoding RNA POM121 transmembrane nucleoporin-like 9, pseudogene). A 2-cM region centered on this variant spans 1.2 Mb and includes 21 variants that were associated with CAD at genome-wide significance, most of which are in LD (r 2 > 0.6) with the lead SNP and map to intronic regions of the SPECC1L and ADORA2A genes ( Fig. 4h) .
At the chromosome 12q24.23 (KSR2) locus, the lead SNP rs11830157 (MAF = 0.36) associated with CAD risk in a recessive model (genotypic OR = 1.12) is intronic to KSR2 (kinase suppressor of ras 2) ( Fig. 4i) and overlaps with ENCODE functional elements. KSR2 interacts with multiple proteins, including AMP-activated protein kinase (AMPK), and rare loss-of-function coding variants in KSR2 are associated with severe obesity, hyperphagia and insulin resistance, a phenotype recapitulated in Ksr2-null mice 42 .
At the chromosome 19q13.11 (ZNF507-LOC400684) locus, the lead SNP rs12976411 (MAF = 0.09) lies in a gene for an uncharacterized noncoding RNA (LOC400684) and is 3.4 kb downstream of ZNF507 (Fig. 4j) . The minor allele showed a protective effect in CAD (genotypic OR = 0.69) in the recessive model. ENCODE analysis of this locus suggests that several SNPs, including rs12981453 and rs71351160, which are in strong LD (r 2 > 0.8) and are intronic to ZNF507, overlap with ENCODE functional elements.
DISCUSSION
We demonstrate that the ability of GWAS to investigate the genetic architecture of complex traits is enhanced by the 1000 Genomes Project. Analysis with this reference set has allowed us to conclude that low-frequency variants of larger effect, synthetic associations and indel polymorphisms are unlikely to explain a significant portion of the missing heritability for CAD. Rather, all ten newly identified CAD associations found in the present analysis, as well as all but one of the previously identified loci, are represented by risk alleles with a frequency of >5%. Thus, this comprehensive analysis strongly supports the common disease-common variant hypothesis 43 , given that it was powered to detect variants with MAF <0.05 having OR >1.5. Moreover, risk-associated alleles are significantly clustered within or close to genes and are enriched in regions with functional annotations. Finally, genes implicated by this unbiased approach suggest hypotheses that explore the biology of the arterial vessel wall as a critical component of CAD pathogenesis.
The success of the GWAS meta-analysis strategy in mapping common, small-effect susceptibility variants for complex diseases has leaned heavily on genotype imputation with publically available training sets. The 1000 Genomes Project provides a substantial stepup from the HapMap era in terms of coverage of lower-frequency variants and the integration of indel polymorphism (Fig. 1) . The lead SNPs for four of the ten newly identified CAD loci were either absent or imperfectly tagged (r 2 < 0.8) in the HapMap 2 training set, which reduced the power of discovering these loci in previous GWAS metaanalyses. Although lower-frequency variants often show geographical differentiation 5 , the 1000 Genomes Project phase 1 v3 training set includes numerous low-MAF variants that are tractable to a global meta-analysis that includes ancestry groups from multiple continents. Key SNPs in APOE and PCSK9, which mediate their effects on CAD via LDL cholesterol-linked mechanisms, showed strong associations and reinforce the sensitivity of our 1000 Genomes Project analysis in detecting lower-frequency, imperfectly imputed susceptibility variants that were missed in HapMap-based GWAS.
Association analysis under the customary additive inheritance model widely used in GWAS is optimally powered to detect traits with no dominance variance but conveniently has adequate power to also detect dominantly inherited traits 44 . However, the additive model is systematically underpowered to detect recessively inherited traits, particularly with lower-frequency alleles 44 . This motivated our meta-analysis using a recessive model, which identified two new CAD risk loci, KSR2 and ZNF507-LOC400684, that escaped detection in a conventional additive association scan.
Our GWAS explores two potential sources of missing heritability for CAD, as it includes indels and an extended panel of lowerfrequency variants. Although there was no evidence that indels were systematically enriched for CAD association, they represented 10% of the 202 variants with an FDR q value <5%. In terms of surveying the totality of human genetic variation, the 1.5 million of the 2.7 million lower-frequency variants included in the meta-analysis with power to detect alleles of moderate penetrance (OR > 1.3) might seem modest. Yet the relative paucity of significant associations for these variants and the finding that 15 variants with MAF <0.05 explained 2% of CAD heritability and provided no evidence of synthetic associations will temper expectations for the role of low-frequency variants in CAD susceptibility, specifically with respect to risk prediction in a population-based setting. It is important to acknowledge that GWAS analysis based on SNP array data has limited power to resolve genes with rare mutation burdens. For example, LDLR 45 , APOA5 (ref. 45) , APOC3 (ref. 46 ) and NPC1L1 (ref. 47 ) are loaded with risk-conferring or protective mutations for CAD. These mutations were only discovered by whole-exome sequencing studies in large series of cases and controls and explain less than 1% of the missing heritability for CAD 45 .
Annotation analysis showed that the CAD-associated variants were significantly clustered within or close to genes. Furthermore, there was strong and independent enrichment for overlap of the CAD associations with ENCODE features, particularly in cell types relevant to CAD pathogenesis. This phenomenon has previously been reported for other diseases and traits 48 and can guide candidate gene nomination and the design of future functional studies. We found few suggestions of overlap with risk factor QTLs or eQTLs in available data sets; this may in part reflect that the use of proxy variants can be limiting in cross-referencing the 1000 Genomes Project and HapMap association databases.
Coronary atherosclerosis underlies the development of the vast majority of myocardial infarction cases; therefore, the two are intimately related. However, additional factors, such as plaque vulnerability and the extent of the thrombotic reaction to plaque disruption, may predispose to myocardial infarction in the presence A r t i c l e s of CAD 49 . We confirmed that ABO is particularly associated with risk of myocardial infarction 50 , suggesting that this locus may specifically increase the risk of plaque rupture and/or thrombosis. In contrast, HDAC9 showed a stronger association with CAD than with myocardial infarction, suggesting that it might predispose to atherosclerosis but not the precipitant events leading to a myocardial infarction. However, HDAC9 shows even stronger association with ischemic strokes involving thrombosis or embolism due to atherosclerosis of a large artery 51 . Although further epidemiological as well as experimental data are required to substantiate these findings, they suggest that certain loci may affect distinct mechanisms related to the development and progression of CAD.
Several of the genes implicated thus far in large-scale analyses of CAD susceptibility encode proteins with a known role in the biology of risk factors for CAD, notably circulating lipid levels and the metabolism of lipoproteins; other susceptibility genes are related to other known atherosclerosis risk factors, including genes implicated in systemic inflammation and hypertension. Such findings are unsurprising, partly because of the undoubted importance of these known risk factors in the etiology of CAD but also because some of the previous analyses particularly targeted genes involved in risk factor traits; for example, HumanCVD BeadChip 52 design was based on candidate genes, and the Metabochip studies 3,53 drew on earlier association data with risk factor traits as well as an earlier HapMap 2based CAD GWAS meta-analysis 54 . The current experiment adopts a completely unbiased approach and, to our knowledge, is the first to do so at very large scale. In this respect, it is notable that, for some of the newly identified loci where genomic data, biological precedent and eQTL associations suggest a plausible candidate gene for CAD, the genes so implicated have well-documented roles in vessel wall biology. Their gene products are involved in diverse processes, including cell adhesion and leukocyte and VSMC migration (SWAP70 (ref. 26 It is important to note that these putative new susceptibility genes require substantial further investigation and validation before firm links to vascular biology can be established. A number of preventative strategies target the vessel wall (control of blood pressure and smoking cessation), but the large majority of existing drug treatments for lowering CAD risk operate through manipulation of circulating lipid levels and few directly target vessel wall processes. Detailed investigation of new aspects of vessel wall biology that are implicated by genetic association but have not previously been explored in atherosclerosis may provide new insights into the complex etiology of disease and, hence, identify new targets.
URLs. Ensembl database, http://www.ensembl.org/; University of Chicago eQTL browser, http://eqtl.uchicago.edu/cgi-bin/gbrowse/ eqtl/; Genotype-Tissue Expression (GTEx) Portal, http://www.gtexportal.org/home/; Geuvadis Data Browser, http://www.ebi.ac.uk/ Tools/geuvadis-das/; CARDIoGRAMplusC4D Consortium, http:// www.cardiogramplusc4d.org/.
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